Betahistine Mesilate

(BANM, rINNM)
Synonyms: Betahistiinimesilaatti; Betahistin-dimesylát; Bétahistine, mésilate de; Betahistine Mesylate; Betahistini Dimesilas; Betahistini mesilas; Betahistinmesilat; Betahistino mesilatas; Betahisztin-mezilát; Mesilato de betahistina. N-Methyl-2-(2-pyridyl)ethylamine bismethanesulphonate.
Cyrillic synonym: Бетагистина Мезилат.

💊 Chemical information

Chemical formula: C8H12N2,(CH4O3S)2 = 328.4.
CAS — 54856-23-4.
ATC — N07C A01.
ATC Vet — QN07CA01.

Pharmacopoeias.

In Eur. and Jpn.

Ph. Eur. 6.2

(Betahistine Mesilate). A white or almost white, crystalline, very hygroscopic powder. Very soluble in water; freely soluble in alcohol; very slightly soluble in isopropyl alcohol. A 10% solution in water has a pH of 2.0 to 3.0. Store in airtight containers.

💊 Adverse Effects

Gastrointestinal disturbances, headache, skin rashes, and pruritus have been reported.

💊 Precautions

Betahistine should not be given to patients with phaeochromocytoma. It should be given with care to patients with asthma, peptic ulcer disease, or a history of peptic ulcer disease.

Porphyria.

Betahistine hydrochloride is considered to be unsafe in patients with porphyria because it has been shown to be porphyrinogenic in in-vitro systems.

💊 Uses and Administration

Betahistine is an analogue of histamine and is claimed to improve the microcirculation of the labyrinth resulting in reduced endolymphatic pressure. It is used to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Ménière’s disease. Betahistine is given orally as the hydrochloride or mesilate. The usual initial dose (of the hydrochloride) is 16 mg three times daily taken preferably with meals; maintenance doses are generally in the range of 24 to 48 mg daily. Betahistine mesilate is used in similar doses.
1.
Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs 2001; 15: 853–70
2. James AL, Burton MJ. Betahistine for Ménière’s disease or syndrome. Available in The Cochrane Database of Systematic Reviews; Issu
1. Chichester: John Wiley; 2001 (accessed 30/05/06).

💊 Preparations

BP 2008: Betahistine Dihydrochloride Tablets.

Proprietary Preparations

Arg.: Meniex; Microser; Ronistina; Travelmin; Austral.: Serc; Austria: Betaserc; Belg.: Betahistop; Betaserc; Docbetahi; Braz.: Betaserc; Labirin; Canad.: Serc; Chile: Microser; Cz.: Avertin; Betaserc; Microser; Polvertic; Zenostig; Denm.: Betaserc; Fin.: Betaserc; Fr.: Betaserc; Evolis†; Extovyl; Lectil; Serc; Ger.: Aequamen; Betavert; Melopat†; Vasomotal; Gr.: Antivom; Betaserc; Katabexin†; Ribrain; Riva; Hong Kong: Beta-Synto; Betaserc; Bymeniere; Meniero; Merislon; Hung.: Betagen; Betaserc; Elven; Microser; India: Betahist†; Vertin; Indon.: Betaserc; Merislon; Mertigo; Nover ty; Vastigo; Vercure; Versilon; Ver tex; Irl.: By-Vertin; Serc; Vertigon; Israel: Agiserc; Betistine; Ital.: Microser; Sincrover; Vertiserc; Jpn: Merislon; Malaysia: Alfinor; Betaserc; Merislon; Mex.: Serc; Neth.: Betaserc; NZ: Serc†; Vergo; Philipp.: Merislon; Serc; Vertilate; Pol.: Betaserc; Histimerck; Microser; Port.: Betaserc; Rus.: Betaserc (Бетасерк); Vestibo (Вестибо); S.Afr.: Serc; Singapore: Betaserc; Merislon; Spain: Fidium; Serc; Switz.: Betaserc; Thai.: Behistin; Betahist-B; Merislon; Merlin; Serc; Turk.: Betaserc; Vasoserc; UK: Serc; Venez.: Microser; Serc.
Published January 15, 2019.